The KEYNOTE-590 phase III trial aimed to evaluate 5-yr survival for 1L pembro + chemo vs. pbo + chemo in advanced esophageal cancer patients. The primary endpoints were OS in ESCC with PD-L1 CPS ≥10 and OS/PFS per RECIST v1.1 in all ESCC patients. The results demonstrated lasting effectiveness without new safety issues […]...
ASCO-GI-2024
Feb 01
-Feb 10, 2024